Most cited papers from Acentech (United States)

Acentech (United States)

What are the most cited papers from Acentech (United States)?

The most cited paper from Acentech (United States) is "Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer" (Dennis J. Slamon, William J. Godolphin, Lovell Allan Jones et al., 1989), with 6,879 citations. Next come "Membrane transporters in drug development" (3,373) and "Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis" (3,223).

Published TypeFieldAccessCitations

Showing 50 of 60 papers. Every paper with more than 382 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer Dennis J. Slamon, William J. Godolphin, Lovell Allan Jones et al. · Science	12 May 1989	6,879
2	Membrane transporters in drug development Kathleen M. Giacomini et al. · Nature Reviews Drug Discovery ReviewOpen access	Mar 2010	3,373
3	Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis HEIDI S. PHILLIPS, Samir Kharbanda, Ruihuan Chen et al. · Cancer Cell Open access	Mar 2006	3,223
4	A system for shotgun DNA sequencing Joachim W. Messing, Roberto Crea, Peter H. Seeburg · Nucleic Acids Research Open access	1981	2,652
5	Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome Carole L. Marcus, Lee J. Brooks, Kari A. Draper et al. · PEDIATRICS	27 Aug 2012	2,431
6	Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin Diane Pennica, Glenn E. Nedwin, Joel S. Hayflick et al. · Nature	Dec 1984	1,746
7	Targeted Disruption of the Stat1 Gene in Mice Reveals Unexpected Physiologic Specificity in the JAK–STAT Signaling Pathway Marco Antonio Meraz‐Ríos, J. Michael White, Kathleen C. F. Sheehan et al. · Cell Open access	Feb 1996	1,672
8	Recombinant Human Tumor Necrosis Factor-α: Effects on Proliferation of Normal and Transformed Cells in Vitro Barry J. Sugarman, Bharat Bhushan Aggarwal, Philip E. Hass et al. · Science	22 Nov 1985	1,597
9	Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. C A Dinarello, Joseph G. Cannon, STEWART M. WOLFF et al. · The Journal of Experimental Medicine Open access	Jun 1986	1,481
10	VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain Zheng Gang Zhang, Li Zhang, Quan Jiang et al. · Journal of Clinical Investigation Open access	Oct 2000	1,315
11	GDNF: a Potent Survival Factor for Motoneurons Present in Peripheral Nerve and Muscle Christopher E. Henderson, HEIDI S. PHILLIPS, Richard A. Pollock et al. · Science	11 Nov 1994	1,282
12	Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α Samuel Joseph Leibovich, Peter J. Polverini, H. Michael Shepard et al. · Nature	Oct 1987	1,218
13	Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset Wayne M. Clark, S. Wissman, Gregory W. Albers et al. · JAMA Open access	Dec 1999	1,197
14	Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma Wyndham Hopkins Wilson et al. · Nature Medicine Open access	20 Jul 2015	1,130
15	The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog Donna M. Stone, Mary Hynes, Mark P. Armanini et al. · Nature	Nov 1996	1,121
16	The VIVA Trial Timothy D. Henry, Brian Herb Annex, George R. McKendall et al. · Circulation	18 Mar 2003	1,030
17	Association of Systemic Lupus Erythematosus with C8orf13–BLK and ITGAM–ITGAX Geoffrey Hom et al. · New England Journal of Medicine Open access	20 Jan 2008	925
18	Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors. M. Refaat Shalaby, Bharat B Aggarwal, Emily Rinderknecht et al. · The Journal of Immunology	Sep 1985	915
19	Characterization of receptors for human tumour necrosis factor and their regulation by γ-interferon Bharat Bhushan Aggarwal, Thomas E. Eessalu, Philip E. Hass · Nature	19 Dec 1985	885
20	Treatment of HER2-positive breast cancer: current status and future perspectives Carlos L. Arteaga, Mark X. Sliwkowski, Charles Kent Osborne et al. · Nature Reviews Clinical Oncology Review	29 Nov 2011	882
21	Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Alicia M. Viloria Petit, Janusz W. Rak, Mien‐Chie Hung et al. · PubMed Open access	Dec 1997	842
22	Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials David M. Brown, Quan Dong Nguyen, Dennis M. Marcus et al. · Ophthalmology Open access	22 May 2013	831
23	Down-regulation of Fc(ε)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody Donald W. MacGlashan, Bruce Scott Bochner, D C Adelman et al. · The Journal of Immunology	Feb 1997	828
24	Consensus Guidelines for the Diagnosis and Treatment of Growth Hormone (GH) Deficiency in Childhood and Adolescence: Summary Statement of the GH Research Society G. R. Society · The Journal of Clinical Endocrinology & Metabolism	Nov 2000	824
25	A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus Vesela Gateva et al. · Nature Genetics Open access	18 Oct 2009	816
26	New Neurons Follow the Flow of Cerebrospinal Fluid in the Adult Brain Kazunobu Sawamoto, Hynek Wichterle, Óscar González-Pérez et al. · Science	12 Jan 2006	803
27	Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu Christopher C. Benz, Gary K. Scott, Jay C. Sarup et al. · Breast Cancer Research and Treatment	Jun 1992	761
28	Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism Catherine Werts, Richard I. Tapping, John C. Mathison et al. · Nature Immunology	Apr 2001	741
29	Measuring Patients’ Trust in their Primary Care Providers Mark A. Hall, Beiyao Zheng, Elizabeth Dugan et al. · Medical Care Research and Review Open access	Sep 2002	667
30	Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity Patrick W. Gray, Bharat Bhushan Aggarwal, Charles V. Benton et al. · Nature	Dec 1984	641
31	Rational Design of Potent Antagonists to the Human Growth Hormone Receptor Germaine Fuh, Brian C. Cunningham, Rikiro Fukunaga et al. · Science	19 Jun 1992	637
32	Benzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation In Animal Cells Guy L. James, Joseph L. Goldstein, Michael Scott Brown et al. · Science	25 Jun 1993	635
33	Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism. Paul J. Godowski, David W. M. Leung, Lillian R. Meacham et al. · Proceedings of the National Academy of Sciences Open access	Oct 1989	605
34	Regulation of Gi and Go by mastoparan, related amphiphilic peptides, and hydrophobic amines. Mechanism and structural determinants of activity. Tsutomu Higashijima, John P. Burnier, Elliott M. Ross · Journal of Biological Chemistry Open access	Aug 1990	602
35	Engaging neuroscience to advance translational research in brain barrier biology Edward A. Neuwelt, Björn Bauer, Christoph Fahlke et al. · Nature reviews. Neuroscience ReviewOpen access	18 Feb 2011	591
36	Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. A E Koch, Lisa A. Harlow, G. Kenneth Haines et al. · The Journal of Immunology	Apr 1994	575
37	Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer Daniel V.T. Catenacci et al. · Journal of Clinical Oncology Open access	3 Nov 2015	563
38	Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors Patricia Mucci LoRusso, Charles M. Rudin, Josina C. Reddy et al. · Clinical Cancer Research Open access	8 Feb 2011	548
39	The neu Gene: an erb B-Homologous Gene Distinct from and Unlinked to the Gene Encoding the EGF Receptor Alan L. Schechter, Mien‐Chie Hung, Lalitha Vaidyanathan et al. · Science	6 Sep 1985	518
40	Human Lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal localization Glenn E. Nedwin, Susan L. Naylor, Alan Y. Sakaguchi et al. · Nucleic Acids Research Open access	1985	513
41	Macrophage deactivating factor and transforming growth factors- beta 1 - beta 2 and - beta 3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-gamma. Aihao H. Ding, Carl Nathan, Jeannette L. Graycar et al. · The Journal of Immunology	Aug 1990	501
42	Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients Robert L. Yauch, Thomas Januario, David A. Eberhard et al. · Clinical Cancer Research	15 Dec 2005	495
43	Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer David Robert Spigel, Thomas J. Ervin, Rodryg Ramlau et al. · Journal of Clinical Oncology Open access	7 Oct 2013	483
44	Progressive Fibrosis in Nonalcoholic Steatohepatitis: Association With Altered Regeneration and a Ductular Reaction Michelle M. Richardson, Julie R. Jonsson, Elizabeth Ellen Powell et al. · Gastroenterology Open access	17 May 2007	482
45	Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus Stacy L. Musone, Kimberly E. Taylor, Timothy Tehua Lu et al. · Nature Genetics Open access	Aug 2008	472
46	Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity. Antonio Rodríguez Celada, Patrick W. Gray, Emily Rinderknecht et al. · The Journal of Experimental Medicine Open access	Jul 1984	467
47	Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study Sarbjit S. Saini, Carsten Bindslev‐Jensen, Marcus Maurer et al. · Journal of Investigative Dermatology Open access	21 Jul 2014	467
48	Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial Clifton O. Bingham, R. John Looney, Atul A. Deodhar et al. · Arthritis & Rheumatism	28 Dec 2009	466
49	TULP3 bridges the IFT-A complex and membrane phosphoinositides to promote trafficking of G protein-coupled receptors into primary cilia Saikat Mukhopadhyay, Xiaohui Wen, Ben Chih et al. · Genes & Development Open access	Oct 2010	463
50	Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a) Michelle Anne Lowes, Francesca Chamian, Maria Veronica Abello et al. · Proceedings of the National Academy of Sciences Open access	27 Dec 2005	454

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.